{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PD-1 immune checkpoint inhibitor and cancer immunotherapy", "apoptosis", "colchicine alkaloid", "colon cancer cells", "mesoporous silica nanoparticles", "targeted delivery system"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "31936103", "DateRevised": {"Year": "2024", "Month": "03", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "01", "Day": "07"}], "Language": ["eng"], "ELocationID": ["144", "10.3390/cancers12010144"], "Journal": {"ISSN": "2072-6694", "JournalIssue": {"Volume": "12", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jan", "Day": "07"}}, "Title": "Cancers", "ISOAbbreviation": "Cancers (Basel)"}, "ArticleTitle": "Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles.", "Abstract": {"AbstractText": ["Antimitotics are important anticancer agents and include the natural alkaloid prodrug colchicine (COL). However, a major challenge of using COL as an anticancer drug is its cytotoxicity. We developed a novel drug delivery system (DDS) for COL using mesoporous silica nanoparticles (MSNs). The MSNs were functionalized with phosphonate groups, loaded with COL, and coated with folic acid chitosan-glycine complex. The resulting nanoformulation, called MSNsPCOL/CG-FA, was tested for action against cancer and normal cell lines. The anticancer effect was highly enhanced for MSNsPCOL/CG-FA compared to COL. In the case of HCT116 cells, 100% inhibition was achieved. The efficiency of MSNsPCOL/CG-FA ranked in this order: HCT116 (colon cancer) > HepG2 (liver cancer) > PC3 (prostate cancer). MSNsPCOL/CG-FA exhibited low cytotoxicity (4%) compared to COL (~60%) in BJ1 normal cells. The mechanism of action was studied in detail for HCT116 cells and found to be primarily intrinsic apoptosis caused by an enhanced antimitotic effect. Furthermore, a contribution of genetic regulation (metastasis-associated lung adenocarcinoma transcript 1 (MALAT 1), and microRNA (mir-205)) and immunotherapy effects (angiopoietin-2 (Ang-2 protein) and programmed cell death protein 1 (PD-1) was found. Therefore, this study shows enhanced anticancer effects and reduced cytotoxicity of COL with targeted delivery compared to free COL and is a novel method of developing cancer immunotherapy using a low-cost small-molecule natural prodrug."]}, "AuthorList": [{"Identifier": ["0000-0001-8413-6738"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Nanostructures, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}, {"Identifier": [], "Affiliation": "Medicinal and Aromatic Plants Research Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Dokki, Giza 12622, Egypt."}], "LastName": "AbouAitah", "ForeName": "Khaled", "Initials": "K"}, {"Identifier": ["0000-0002-7129-4259"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Dokki, Giza 12622, Egypt."}], "LastName": "Hassan", "ForeName": "Heba A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Nanostructures, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}], "LastName": "Swiderska-Sroda", "ForeName": "Anna", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Dokki, Giza 12622, Egypt."}], "LastName": "Gohar", "ForeName": "Lamiaa", "Initials": "L"}, {"Identifier": ["0000-0002-3031-3599"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Cairo 11511, Egypt."}], "LastName": "Shaker", "ForeName": "Olfat G", "Initials": "OG"}, {"Identifier": ["0000-0002-6106-5188"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Nanostructures, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}], "LastName": "Wojnarowicz", "ForeName": "Jacek", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Nanostructures, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}], "LastName": "Opalinska", "ForeName": "Agnieszka", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Semiconductor Characterization, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}], "LastName": "Smalc-Koziorowska", "ForeName": "Julita", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Nanostructures, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}], "LastName": "Gierlotka", "ForeName": "Stanislaw", "Initials": "S"}, {"Identifier": ["0000-0001-8521-0688"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Nanostructures, Institute of High Pressure Physics, Polish Academy of Sciences, Sokolowska 29/37, 01-142 Warsaw, Poland."}], "LastName": "Lojkowski", "ForeName": "Witold", "Initials": "W"}], "GrantList": [{"GrantID": "Internal funding", "Agency": "National Research Centre (NRC, Egypt)", "Country": ""}, {"GrantID": "STRATEGMED3/306888/3/ NCBR/2017, project iTE, Poland", "Agency": "National Center for Research and Development, Poland", "Country": ""}, {"GrantID": "CePT project, reference: POIG.02.02.00-14-024/08", "Agency": "European Regional Development Fund within the Operational Programme \"Innovative Economy\"", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cancers (Basel)", "NlmUniqueID": "101526829", "ISSNLinking": "2072-6694"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Kaplan M.M., Alling D.W., Zimmerman H.J., Wolfe H.J., Sepersky R.A., Hirsch G.S., Elta G.H., Glick K.A., Eagen K.A. A prospective trial of colchicine for primary biliary cirrhosis. N. Engl. J. Med. 1986;315:1448\u20131454. doi: 10.1056/NEJM198612043152304.", "ArticleIdList": ["10.1056/NEJM198612043152304", "3537784"]}, {"Citation": "Cohen A.S., Rubinow A., Anderson J.J., Skinner M., Mason J.H., Libbey C., Kayne H. Survival of patients with primary (AL) amyloidosis: Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973) Am. J. Med. 1987;82:1182\u20131190. doi: 10.1016/0002-9343(87)90222-1.", "ArticleIdList": ["10.1016/0002-9343(87)90222-1", "3605135"]}, {"Citation": "Gigax J.H., Robison J.R. The Successful Treatment of Intraurethral Condyloma Acuminata with Colchicine. J. Urol. 1971;105:809\u2013811. doi: 10.1016/S0022-5347(17)61636-7.", "ArticleIdList": ["10.1016/S0022-5347(17)61636-7", "5091712"]}, {"Citation": "Sampedro-N\u00fa\u00f1ez M., Serrano-Somavilla A., Adrados M., Cameselle-Teijeiro J.M., Blanco-Carrera C., Cabezas-Agricola J.M., Mart\u00ednez-Hern\u00e1ndez R., Mart\u00edn-P\u00e9rez E., Mu\u00f1oz de Nova J.L., D\u00edaz J.\u00c1., et al. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sci. Rep. 2018;8:17812. doi: 10.1038/s41598-018-36129-1.", "ArticleIdList": ["10.1038/s41598-018-36129-1", "PMC6292913", "30546030"]}, {"Citation": "Bhattacharyya B., Panda D., Gupta S., Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med. Res. Rev. 2008;28:155\u2013183. doi: 10.1002/med.20097.", "ArticleIdList": ["10.1002/med.20097", "17464966"]}, {"Citation": "Huang Z., Xu Y., Peng W. Colchicine induces apoptosis in HT29 human colon cancer cells via the AKT and c-Jun N-terminal kinase signaling pathways. Mol. Med. Rep. 2015;12:5939\u20135944. doi: 10.3892/mmr.2015.4222.", "ArticleIdList": ["10.3892/mmr.2015.4222", "26299305"]}, {"Citation": "Zhang L., Yang Z., Granieri L., Pasculescu A., Datti A., Asa S.L., Xu Z., Ezzat S. High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. Oncotarget. 2016;7:19948\u201319959. doi: 10.18632/oncotarget.7890.", "ArticleIdList": ["10.18632/oncotarget.7890", "PMC4991430", "26942566"]}, {"Citation": "Cho J.H., Joo Y.H., Shin E.Y., Park E.J., Kim M.S. Anticancer Effects of Colchicine on Hypopharyngeal Cancer. Anticancer Res. 2017;37:6269\u20136280. doi: 10.21873/anticanres.12078.", "ArticleIdList": ["10.21873/anticanres.12078", "29061810"]}, {"Citation": "Lin Z.Y., Kuo C.H., Wu D.C., Chuang W.L. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J. Med. Sci. 2016;32:68\u201373. doi: 10.1016/j.kjms.2015.12.006.", "ArticleIdList": ["10.1016/j.kjms.2015.12.006", "26944324"]}, {"Citation": "Kumar A., Sharma P.R., Mondhe D.M. Potential anticancer role of colchicine-based derivatives: An overview. Anti Cancer Drugs. 2017;28:250\u2013262. doi: 10.1097/CAD.0000000000000464.", "ArticleIdList": ["10.1097/CAD.0000000000000464", "28030380"]}, {"Citation": "Kumar A., Singh B., Sharma P.R., Bharate S.B., Saxena A.K., Mondhe D.M. A novel microtubule depolymerizing colchicine analogue triggers apoptosis and autophagy in HCT-116 colon cancer cells. Cell Biochem. Funct. 2016;34:69\u201381. doi: 10.1002/cbf.3166.", "ArticleIdList": ["10.1002/cbf.3166", "26919061"]}, {"Citation": "Choi A.R., Kim J.H., Cheon J.H., Kim H.S., Yoon S. Attenuation of Colchicine Toxicity in Drug-resistant Cancer Cells by Co-treatment with Anti-malarial Drugs. Anticancer Res. 2016;36:5859\u20135866. doi: 10.21873/anticanres.11171.", "ArticleIdList": ["10.21873/anticanres.11171", "27793909"]}, {"Citation": "Gupta R.S., Dudani A.K. Mechanism of action of antimitotic drugs: A new hypothesis based on the role of cellular calcium. Med. Hypotheses. 1989;28:57\u201369. doi: 10.1016/0306-9877(89)90154-0.", "ArticleIdList": ["10.1016/0306-9877(89)90154-0", "2648125"]}, {"Citation": "Gascoigne K.E., Taylor S.S. How do anti-mitotic drugs kill cancer cells? J. Cell Sci. 2009;122:2579\u20132585. doi: 10.1242/jcs.039719.", "ArticleIdList": ["10.1242/jcs.039719", "19625502"]}, {"Citation": "Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: A molecular definition. Oncogene. 2004;23:2825\u20132837. doi: 10.1038/sj.onc.1207528.", "ArticleIdList": ["10.1038/sj.onc.1207528", "15077146"]}, {"Citation": "Qi C., Wang X., Shen Z., Chen S., Yu H., Williams N., Wang G. Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells. Cell Res. 2018;28:544\u2013555. doi: 10.1038/s41422-018-0018-6.", "ArticleIdList": ["10.1038/s41422-018-0018-6", "PMC5951888", "29497138"]}, {"Citation": "Fong A., Durkin A., Lee H. The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy. Int. J. Mol. Sci. 2019;20:586. doi: 10.3390/ijms20030586.", "ArticleIdList": ["10.3390/ijms20030586", "PMC6387102", "30704031"]}, {"Citation": "Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010;207:2175\u20132186. doi: 10.1084/jem.20100637.", "ArticleIdList": ["10.1084/jem.20100637", "PMC2947081", "20819923"]}, {"Citation": "Silva R., Gullo I., Carneiro F. The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: A comprehensive review and future perspectives. Porto Biomed. J. 2016;1:4\u201311. doi: 10.1016/j.pbj.2016.03.004.", "ArticleIdList": ["10.1016/j.pbj.2016.03.004", "PMC6806944", "32258540"]}, {"Citation": "Yao H., Wang H., Li C., Fang J.-Y., Xu J. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Front. Immunol. 2018;9:1774. doi: 10.3389/fimmu.2018.01774.", "ArticleIdList": ["10.3389/fimmu.2018.01774", "PMC6077319", "30105035"]}, {"Citation": "Berntsson J., Eberhard J., Nodin B., Leandersson K., Larsson A.H., Jirstr\u00f6m K. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncoimmunology. 2018;7:e1465165. doi: 10.1080/2162402X.2018.1465165.", "ArticleIdList": ["10.1080/2162402X.2018.1465165", "PMC6136864", "30221062"]}, {"Citation": "Syn N.L., Teng M.W.L., Mok T.S.K., Soo R.A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731\u2013e741. doi: 10.1016/S1470-2045(17)30607-1.", "ArticleIdList": ["10.1016/S1470-2045(17)30607-1", "29208439"]}, {"Citation": "Franchini D.-M., Lanvin O., Tosolini M., Patras de Campaigno E., Cammas A., P\u00e9ricart S., Scarlata C.-M., Lebras M., Rossi C., Ligat L., et al. Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Rep. 2019;26:94\u2013107. doi: 10.1016/j.celrep.2018.12.014.", "ArticleIdList": ["10.1016/j.celrep.2018.12.014", "30605689"]}, {"Citation": "Ades S. Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice. Oncology. 2009;23:162\u2013167.", "ArticleIdList": ["19323297"]}, {"Citation": "Banerjee A., Pathak S., Subramanium V.D., Dharanivasan G., Murugesan R., Verma R.S. Strategies for targeted drug delivery in treatment of colon cancer: Current trends and future perspectives. Drug Discov. Today. 2017;22:1224\u20131232. doi: 10.1016/j.drudis.2017.05.006.", "ArticleIdList": ["10.1016/j.drudis.2017.05.006", "28545838"]}, {"Citation": "AbouAitah K., Swiderska-Sroda A., Farghali A.A., Wojnarowicz J., Stefanek A., Gierlotka S., Opalinska A., Allayeh A.K., Ciach T., Lojkowski W. Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action. Oncotarget. 2018;9:26466\u201326490. doi: 10.18632/oncotarget.25470.", "ArticleIdList": ["10.18632/oncotarget.25470", "PMC5995188", "29899871"]}, {"Citation": "Shahein S.A., Aboul-Enein A.M., Higazy I.M., Abou-Elella F., Lojkowski W., Ahmed E.R., Mousa S.A., AbouAitah K. Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release. Int. J. Nanomed. 2019;14:5503\u20135526. doi: 10.2147/IJN.S206899.", "ArticleIdList": ["10.2147/IJN.S206899", "PMC6650459", "31410001"]}, {"Citation": "Cauda V., Engelke H., Sauer A., Arcizet D., Brauchle C., Radler J., Bein T. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett. 2010;10:2484\u20132492. doi: 10.1021/nl100991w.", "ArticleIdList": ["10.1021/nl100991w", "20515041"]}, {"Citation": "Muvaffak A., Gurhan I., Hasirci N. Prolonged cytotoxic effect of colchicine released from biodegradable microspheres. J. Biomed. Mater. Res. Part B Appl. Biomater. 2004;71:295\u2013304. doi: 10.1002/jbm.b.30092.", "ArticleIdList": ["10.1002/jbm.b.30092", "15386399"]}, {"Citation": "Polshettiwar V., Cha D., Zhang X., Basset J.M. High-surface-area silica nanospheres (KCC-1) with a fibrous morphology. Angew. Chem. Int. Ed. Engl. 2010;49:9652\u20139656. doi: 10.1002/anie.201003451.", "ArticleIdList": ["10.1002/anie.201003451", "20680958"]}, {"Citation": "Chang B., Chen D., Wang Y., Chen Y., Jiao Y., Sha X., Yang W. Bioresponsive Controlled Drug Release Based on Mesoporous Silica Nanoparticles Coated with Reductively Sheddable Polymer Shell. Chem. Mater. 2013;25:574\u2013585. doi: 10.1021/cm3037197.", "ArticleIdList": ["10.1021/cm3037197"]}, {"Citation": "Castillo R.R., Lozano D., Gonz\u00e1lez B., Manzano M., Izquierdo-Barba I., Vallet-Reg\u00ed M. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update. Expert Opin. Drug Deliv. 2019;16:415\u2013439. doi: 10.1080/17425247.2019.1598375.", "ArticleIdList": ["10.1080/17425247.2019.1598375", "PMC6667337", "30897978"]}, {"Citation": "Lukey M.J., Katt W.P., Cerione R.A. Targeting amino acid metabolism for cancer therapy. Drug Discov. Today. 2017;22:796\u2013804. doi: 10.1016/j.drudis.2016.12.003.", "ArticleIdList": ["10.1016/j.drudis.2016.12.003", "PMC5429979", "27988359"]}, {"Citation": "Fern\u00e1ndez M., Javaid F., Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem. Sci. 2018;9:790\u2013810. doi: 10.1039/C7SC04004K.", "ArticleIdList": ["10.1039/C7SC04004K", "PMC5890329", "29675145"]}, {"Citation": "Sabharanjak S., Mayor S. Folate receptor endocytosis and trafficking. Adv. Drug Deliv. Rev. 2004;56:1099\u20131109. doi: 10.1016/j.addr.2004.01.010.", "ArticleIdList": ["10.1016/j.addr.2004.01.010", "15094209"]}, {"Citation": "Zwicke G.L., Ali Mansoori G., Jeffery C.J. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3:18496. doi: 10.3402/nano.v3i0.18496.", "ArticleIdList": ["10.3402/nano.v3i0.18496", "PMC3521101", "23240070"]}, {"Citation": "AbouAitah K., Farghali A., Swiderska-Sroda A., Lojkowski W., Razin A., Khedr M.K. Mesoporous silica materials in drug delivery system: pH/glutathione-responsive release of poorly water-soluble pro-drug quercetin from two and three-dimensional pore-structure nanoparticles. J. Nanomed. Nanotechnol. 2016:7. doi: 10.4172/2157-7439.1000360.", "ArticleIdList": ["10.4172/2157-7439.1000360"]}, {"Citation": "AbouAitah K.E., Farghali A., Swiderska-Sroda A., Lojkowski W., Razin A., Khedr M.K. pH-controlled release system for curcumin based on functionalized dendritic mesoporous silica nanoparticles. J. Nanomed. Nanotechnol. 2016:7. doi: 10.4172/2157-7439.1000351.", "ArticleIdList": ["10.4172/2157-7439.1000351"]}, {"Citation": "Menon N., Leong D.T. Cytotoxic Effects of Phosphonate-Functionalized Mesoporous Silica Nanoparticles. ACS Appl. Mater. Interfaces. 2016;8:2416\u20132422. doi: 10.1021/acsami.5b11741.", "ArticleIdList": ["10.1021/acsami.5b11741", "26741564"]}, {"Citation": "Villanueva A., Canete M., Roca A.G., Calero M., Veintemillas-Verdaguer S., Serna C.J., Morales Mdel P., Miranda R. The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology. 2009;20:115103. doi: 10.1088/0957-4484/20/11/115103.", "ArticleIdList": ["10.1088/0957-4484/20/11/115103", "19420433"]}, {"Citation": "Yue Z.-G., Wei W., Lv P.-P., Yue H., Wang L.-Y., Su Z.-G., Ma G.-H. Surface Charge Affects Cellular Uptake and Intracellular Trafficking of Chitosan-Based Nanoparticles. Biomacromolecules. 2011;12:2440\u20132446. doi: 10.1021/bm101482r.", "ArticleIdList": ["10.1021/bm101482r", "21657799"]}, {"Citation": "Fr\u00f6hlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 2012;7:5577\u20135591. doi: 10.2147/IJN.S36111.", "ArticleIdList": ["10.2147/IJN.S36111", "PMC3493258", "23144561"]}, {"Citation": "Zhang S., Gao H., Bao G. Physical Principles of Nanoparticle Cellular Endocytosis. ACS Nano. 2015;9:8655\u20138671. doi: 10.1021/acsnano.5b03184.", "ArticleIdList": ["10.1021/acsnano.5b03184", "PMC5681865", "26256227"]}, {"Citation": "Xin Y., Yin M., Zhao L., Meng F., Luo L. Recent progress on nanoparticle-based drug delivery systems for cancer therapy. Cancer Biol. Med. 2017;14:228\u2013241. doi: 10.20892/j.issn.2095-3941.2017.0052.", "ArticleIdList": ["10.20892/j.issn.2095-3941.2017.0052", "PMC5570600", "28884040"]}, {"Citation": "Tran S., DeGiovanni P.-J., Piel B., Rai P. Cancer nanomedicine: A review of recent success in drug delivery. Clin. Transl. Med. 2017;6:44. doi: 10.1186/s40169-017-0175-0.", "ArticleIdList": ["10.1186/s40169-017-0175-0", "PMC5725398", "29230567"]}, {"Citation": "Chen T., Wu W., Xiao H., Chen Y., Chen M., Li J. Intelligent Drug Delivery System Based on Mesoporous Silica Nanoparticles Coated with an Ultra-pH-Sensitive Gatekeeper and Poly(ethylene glycol) ACS Macro Lett. 2016;5:55\u201358. doi: 10.1021/acsmacrolett.5b00765.", "ArticleIdList": ["10.1021/acsmacrolett.5b00765", "35668579"]}, {"Citation": "Cheung A., Bax H.J., Josephs D.H., Ilieva K.M., Pellizzari G., Opzoomer J., Bloomfield J., Fittall M., Grigoriadis A., Figini M., et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7:52553\u201352574. doi: 10.18632/oncotarget.9651.", "ArticleIdList": ["10.18632/oncotarget.9651", "PMC5239573", "27248175"]}, {"Citation": "Andreu J.M., Perez-Ramirez B., Gorbunoff M.J., Ayala D., Timasheff S.N. Role of the colchicine ring A and its methoxy groups in the binding to tubulin and microtubule inhibition. Biochemistry. 1998;37:8356\u20138368. doi: 10.1021/bi9728553.", "ArticleIdList": ["10.1021/bi9728553", "9622487"]}, {"Citation": "Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer. 2004;4:253\u2013265. doi: 10.1038/nrc1317.", "ArticleIdList": ["10.1038/nrc1317", "15057285"]}, {"Citation": "Lu Y., Chen J., Xiao M., Li W., Miller D.D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm. Res. 2012;29:2943\u20132971. doi: 10.1007/s11095-012-0828-z.", "ArticleIdList": ["10.1007/s11095-012-0828-z", "PMC3667160", "22814904"]}, {"Citation": "Blajeski A.L., Phan V.A., Kottke T.J., Kaufmann S.H. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J. Clin. Investig. 2002;110:91\u201399. doi: 10.1172/JCI13275.", "ArticleIdList": ["10.1172/JCI13275", "PMC151025", "12093892"]}, {"Citation": "Kulshrestha A., Katara G.K., Ibrahim S.A., Patil R., Patil S.A., Beaman K.D. Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. Oncotarget. 2017;8:67017\u201367028. doi: 10.18632/oncotarget.17549.", "ArticleIdList": ["10.18632/oncotarget.17549", "PMC5620153", "28978013"]}, {"Citation": "Cuddihy A.R., O\u2019Connell M.J. Cell-cycle responses to DNA damage in G2. Int. Rev. Cytol. 2003;222:99\u2013140.", "ArticleIdList": ["12503848"]}, {"Citation": "Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: A Link between Cancer Genetics and Chemotherapy. Cell. 2002;108:153\u2013164. doi: 10.1016/S0092-8674(02)00625-6.", "ArticleIdList": ["10.1016/S0092-8674(02)00625-6", "11832206"]}, {"Citation": "Hengartner M.O. The biochemistry of apoptosis. Nature. 2000;407:770\u2013776. doi: 10.1038/35037710.", "ArticleIdList": ["10.1038/35037710", "11048727"]}, {"Citation": "Kim S.-K., Cho S.-M., Kim H., Seok H., Kim S.-O., Kwon T.K., Chang J.-S. The colchicine derivative CT20126 shows a novel microtubule-modulating activity with apoptosis. Exp. Mol. Med. 2013;45:e19. doi: 10.1038/emm.2013.38.", "ArticleIdList": ["10.1038/emm.2013.38", "PMC3641401", "23598593"]}, {"Citation": "Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis. 2000;21:485\u2013495. doi: 10.1093/carcin/21.3.485.", "ArticleIdList": ["10.1093/carcin/21.3.485", "10688869"]}, {"Citation": "Boonstra J., Post J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 2004;337:1\u201313. doi: 10.1016/j.gene.2004.04.032.", "ArticleIdList": ["10.1016/j.gene.2004.04.032", "15276197"]}, {"Citation": "Nagappan A., Lee W.S., Yun J.W., Lu J.N., Chang S.-H., Jeong J.-H., Kim G.S., Jung J.-M., Hong S.C. Tetraarsenic hexoxide induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt suppression and p38 MAPK activation in SW620 human colon cancer cells. PLoS ONE. 2017;12:e0174591. doi: 10.1371/journal.pone.0174591.", "ArticleIdList": ["10.1371/journal.pone.0174591", "PMC5371332", "28355296"]}, {"Citation": "McIlwain D.R., Berger T., Mak T.W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 2013;5:a008656. doi: 10.1101/cshperspect.a008656.", "ArticleIdList": ["10.1101/cshperspect.a008656", "PMC3683896", "23545416"]}, {"Citation": "Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440\u2013442. doi: 10.1038/335440a0.", "ArticleIdList": ["10.1038/335440a0", "3262202"]}, {"Citation": "Scherr A.-L., Gdynia G., Salou M., Radhakrishnan P., Duglova K., Heller A., Keim S., Kautz N., Jassowicz A., Elssner C., et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7:e2342. doi: 10.1038/cddis.2016.233.", "ArticleIdList": ["10.1038/cddis.2016.233", "PMC5108319", "27537525"]}, {"Citation": "Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype. Science. 1997;275:967\u2013969. doi: 10.1126/science.275.5302.967.", "ArticleIdList": ["10.1126/science.275.5302.967", "9020077"]}, {"Citation": "Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 1988;319:525\u2013532. doi: 10.1056/NEJM198809013190901.", "ArticleIdList": ["10.1056/NEJM198809013190901", "2841597"]}, {"Citation": "Peyssonnaux C., Eych\u00e8ne A. The Raf/MEK/ERK pathway: New concepts of activation. Biol. Cell. 2001;93:53\u201362. doi: 10.1016/S0248-4900(01)01125-X.", "ArticleIdList": ["10.1016/S0248-4900(01)01125-X", "11730323"]}, {"Citation": "Ikehara N., Semba S., Sakashita M., Aoyama N., Kasuga M., Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int. J. Cancer. 2005;115:943\u2013950. doi: 10.1002/ijc.20957.", "ArticleIdList": ["10.1002/ijc.20957", "15729718"]}, {"Citation": "Erhardt P., Schremser E.J., Cooper G.M. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 1999;19:5308\u20135315. doi: 10.1128/MCB.19.8.5308.", "ArticleIdList": ["10.1128/MCB.19.8.5308", "PMC84374", "10409722"]}, {"Citation": "Zhang T., Chen W., Jiang X., Liu L., Wei K., Du H., Wang H., Li J. Anticancer effects and underlying mechanism of Colchicine on human gastric cancer cell lines in vitro and in vivo. Biosci. Rep. 2019:39. doi: 10.1042/BSR20181802.", "ArticleIdList": ["10.1042/BSR20181802", "PMC6331673", "30429232"]}, {"Citation": "Nagano O., Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95:930\u2013935. doi: 10.1111/j.1349-7006.2004.tb03179.x.", "ArticleIdList": ["10.1111/j.1349-7006.2004.tb03179.x", "15596040"]}, {"Citation": "Chen C., Zhao S., Karnad A., Freeman J.W. The biology and role of CD44 in cancer progression: Therapeutic implications. J. Hematol. Oncol. 2018;11:64. doi: 10.1186/s13045-018-0605-5.", "ArticleIdList": ["10.1186/s13045-018-0605-5", "PMC5946470", "29747682"]}, {"Citation": "Park Y.S., Huh J.W., Lee J.H., Kim H.R. shRNA against CD44 inhibits cell proliferation, invasion and migration, and promotes apoptosis of colon carcinoma cells. Oncol. Rep. 2012;27:339\u2013346. doi: 10.3892/or.2011.1532.", "ArticleIdList": ["10.3892/or.2011.1532", "22076607"]}, {"Citation": "Zhou J.-Y., Chen M., Ma L., Wang X., Chen Y.-G., Liu S.-L. Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer. Oncotarget. 2016;7:7657\u20137666. doi: 10.18632/oncotarget.7084.", "ArticleIdList": ["10.18632/oncotarget.7084", "PMC4884945", "26840024"]}, {"Citation": "Sahlberg S.H., Spiegelberg D., Glimelius B., Stenerlow B., Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells. PLoS ONE. 2014;9:e94621. doi: 10.1371/journal.pone.0094621.", "ArticleIdList": ["10.1371/journal.pone.0094621", "PMC3997403", "24760019"]}, {"Citation": "Schneider M., Huber J., Hadaschik B., Siegers G.M., Fiebig H.H., Schuler J. Characterization of colon cancer cells: A functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer. 2012;12:96. doi: 10.1186/1471-2407-12-96.", "ArticleIdList": ["10.1186/1471-2407-12-96", "PMC3368744", "22433494"]}, {"Citation": "Lakshman M., Subramaniam V., Rubenthiran U., Jothy S. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp. Mol. Pathol. 2004;77:18\u201325. doi: 10.1016/j.yexmp.2004.03.002.", "ArticleIdList": ["10.1016/j.yexmp.2004.03.002", "15215046"]}, {"Citation": "Ponting C.P., Oliver P.L., Reik W. Evolution and Functions of Long Noncoding RNAs. Cell. 2009;136:629\u2013641. doi: 10.1016/j.cell.2009.02.006.", "ArticleIdList": ["10.1016/j.cell.2009.02.006", "19239885"]}, {"Citation": "Zhao M., Wang S., Li Q., Ji Q., Guo P., Liu X. MALAT1: A long non-coding RNA highly associated with human cancers. Oncol. Lett. 2018;16:19\u201326. doi: 10.3892/ol.2018.8613.", "ArticleIdList": ["10.3892/ol.2018.8613", "PMC6006327", "29928382"]}, {"Citation": "Okugawa Y., Toiyama Y., Hur K., Toden S., Saigusa S., Tanaka K., Inoue Y., Mohri Y., Kusunoki M., Boland C.R., et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35:2731\u20132739. doi: 10.1093/carcin/bgu200.", "ArticleIdList": ["10.1093/carcin/bgu200", "PMC4247518", "25280565"]}, {"Citation": "Wu X.S., Wang X.A., Wu W.G., Hu Y.P., Li M.L., Ding Q., Weng H., Shu Y.J., Liu T.Y., Jiang L., et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol. Ther. 2014;15:806\u2013814. doi: 10.4161/cbt.28584.", "ArticleIdList": ["10.4161/cbt.28584", "PMC4049796", "24658096"]}, {"Citation": "Gutschner T., Hammerle M., Eissmann M., Hsu J., Kim Y., Hung G., Revenko A., Arun G., Stentrup M., Gross M., et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180\u20131189. doi: 10.1158/0008-5472.CAN-12-2850.", "ArticleIdList": ["10.1158/0008-5472.CAN-12-2850", "PMC3589741", "23243023"]}, {"Citation": "Yang M.-H., Hu Z.-Y., Xu C., Xie L.-Y., Wang X.-Y., Chen S.-Y., Li Z.-G. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta. 2015;1852:166\u2013174. doi: 10.1016/j.bbadis.2014.11.013.", "ArticleIdList": ["10.1016/j.bbadis.2014.11.013", "PMC4268411", "25446987"]}, {"Citation": "Wu C., Zhu X., Tao K., Liu W., Ruan T., Wan W., Zhang C., Zhang W. MALAT1 promotes the colorectal cancer malignancy by increasing DCP1A expression and miR203 downregulation. Mol. Carcinog. 2018;57:1421\u20131431. doi: 10.1002/mc.22868.", "ArticleIdList": ["10.1002/mc.22868", "29964337"]}, {"Citation": "Esquela-Kerscher A., Slack F.J. Oncomirs\u2014MicroRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:259\u2013269. doi: 10.1038/nrc1840.", "ArticleIdList": ["10.1038/nrc1840", "16557279"]}, {"Citation": "Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843\u2013854. doi: 10.1016/0092-8674(93)90529-Y.", "ArticleIdList": ["10.1016/0092-8674(93)90529-Y", "8252621"]}, {"Citation": "Schetter A.J., Okayama H., Harris C.C. The role of microRNAs in colorectal cancer. Cancer J. 2012;18:244\u2013252. doi: 10.1097/PPO.0b013e318258b78f.", "ArticleIdList": ["10.1097/PPO.0b013e318258b78f", "PMC3397427", "22647361"]}, {"Citation": "Cekaite L., Eide P.W., Lind G.E., Skotheim R.I., Lothe R.A. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 2016;7:6476\u20136505. doi: 10.18632/oncotarget.6390.", "ArticleIdList": ["10.18632/oncotarget.6390", "PMC4872728", "26623728"]}, {"Citation": "Jing N., Yin L., Sun J., Cao Z., Mao W. Expression levels of miR-205 and miR-506 in colon cancer tissues and their relationships with clinicopathological features. Oncol. Lett. 2018;16:4331\u20134336. doi: 10.3892/ol.2018.9146.", "ArticleIdList": ["10.3892/ol.2018.9146", "PMC6126165", "30214569"]}, {"Citation": "Orang A.V., Safaralizadeh R., Hosseinpour Feizi M.A., Somi M.H. Diagnostic and prognostic value of miR-205 in colorectal cancer. Asian Pac. J. Cancer Prev. 2014;15:4033\u20134037. doi: 10.7314/APJCP.2014.15.9.4033.", "ArticleIdList": ["10.7314/APJCP.2014.15.9.4033", "24935592"]}, {"Citation": "Schmittnaegel M., Rigamonti N., Kadioglu E., Cassara A., Wyser Rmili C., Kiialainen A., Kienast Y., Mueller H.J., Ooi C.H., Laoui D., et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 2017:9. doi: 10.1126/scitranslmed.aak9670.", "ArticleIdList": ["10.1126/scitranslmed.aak9670", "28404865"]}, {"Citation": "Kim H., Ahn T.S., Kim C.-J., Bae S.B., Kim H.J., Lee C.-S., Kim T.H., Im J., Lee S.H., Son M.W., et al. Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma. Oncol. Lett. 2017;14:553\u2013560. doi: 10.3892/ol.2017.6203.", "ArticleIdList": ["10.3892/ol.2017.6203", "PMC5494651", "28693205"]}, {"Citation": "Fukumura D., Kloepper J., Amoozgar Z., Duda D.G., Jain R.K. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 2018;15:325\u2013340. doi: 10.1038/nrclinonc.2018.29.", "ArticleIdList": ["10.1038/nrclinonc.2018.29", "PMC5921900", "29508855"]}, {"Citation": "Khalil D.N., Smith E.L., Brentjens R.J., Wolchok J.D. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nature reviews. Clin. Oncol. 2016;13:273\u2013290. doi: 10.1038/nrclinonc.2016.25.", "ArticleIdList": ["10.1038/nrclinonc.2016.25", "PMC5551685", "26977780"]}, {"Citation": "Webb E.S., Liu P., Baleeiro R., Lemoine N.R., Yuan M., Wang Y.-H. Immune checkpoint inhibitors in cancer therapy. J. Biomed. Res. 2018;32:317\u2013326. doi: 10.7555/JBR.31.20160168.", "ArticleIdList": ["10.7555/JBR.31.20160168", "PMC6163118", "28866656"]}, {"Citation": "Ottaviano M., De Placido S., Ascierto P.A. Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma. Virchows Arch. Int. J. Pathol. 2019;474:421\u2013432. doi: 10.1007/s00428-019-02538-4.", "ArticleIdList": ["10.1007/s00428-019-02538-4", "30747264"]}, {"Citation": "Seidel J.A., Otsuka A., Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol. 2018;8:86. doi: 10.3389/fonc.2018.00086.", "ArticleIdList": ["10.3389/fonc.2018.00086", "PMC5883082", "29644214"]}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55\u201363. doi: 10.1016/0022-1759(83)90303-4.", "ArticleIdList": ["10.1016/0022-1759(83)90303-4", "6606682"]}, {"Citation": "Labib M.B., Philoppes J.N., Lamie P.F., Ahmed E.R. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents. Bioorg. Chem. 2018;76:67\u201380. doi: 10.1016/j.bioorg.2017.10.016.", "ArticleIdList": ["10.1016/j.bioorg.2017.10.016", "29153588"]}, {"Citation": "Shaker O.G., Senousy M.A., Elbaz E.M. Association of rs6983267 at 8q24, HULC rs7763881 polymorphisms and serum lncRNAs CCAT2 and HULC with colorectal cancer in Egyptian patients. Sci. Rep. 2017;7:16246. doi: 10.1038/s41598-017-16500-4.", "ArticleIdList": ["10.1038/s41598-017-16500-4", "PMC5701156", "29176650"]}, {"Citation": "Duan W., Du L., Jiang X., Wang R., Yan S., Xie Y., Yan K., Wang Q., Wang L., Zhang X., et al. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2016;7:78850\u201378858. doi: 10.18632/oncotarget.12880.", "ArticleIdList": ["10.18632/oncotarget.12880", "PMC5346682", "27793008"]}, {"Citation": "Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT Method. Methods. 2001;25:402\u2013408. doi: 10.1006/meth.2001.1262.", "ArticleIdList": ["10.1006/meth.2001.1262", "11846609"]}]}], "History": [{"Year": "2019", "Month": "12", "Day": "3"}, {"Year": "2019", "Month": "12", "Day": "25"}, {"Year": "2020", "Month": "1", "Day": "3"}, {"Year": "2020", "Month": "1", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "16", "Hour": "6", "Minute": "1"}, {"Year": "2020", "Month": "1", "Day": "7"}], "PublicationStatus": "epublish", "ArticleIdList": ["31936103", "PMC7017376", "10.3390/cancers12010144", "cancers12010144"]}}]}